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http://www.translational-medicine.com/content/12/1/229RESEARCH Open AccessIdentification of novel epitopes from human
papillomavirus type 18 E7 that can sensitize
PBMCs of multiple HLA class I against human
cervical cancer
Sunghoon Kim1, Hye Won Chung2, Kyoung-Ryul Lee3 and Jong-Baeck Lim4*Abstract
Background: To identify the novel epitopes from the human papillomavirus type 18 E7 which can sensitize PBMCs
of four different major HLA class I A allele.
Methods: Twenty-four synthetic overlapping 15-amino acid peptides were screened by measuring the frequency of
CD8+ cytotoxic T lymphocytes (CTLs)-producing interferon-γ (IFN-γ) by using flow cytometry and ELISpot assays and
selected peptides were validated for cytolytic activity by using the 51Cr release assay. Truncated peptides in the
selected epitopes were tested to determine the important residues using ELISpot and 51Cr release assay.
Results: Among 24 peptides, E781-95DDLRAFQQLFLNTLS (#21) and E789-103LFLNTLSFVCPWCAS (#23) induced
significantly higher Th 1 response including IFN-γ production and in vitro cytotoxicity of PBMCs of four different
HLA-A alleles against cervical cancer cells than that of other peptides and the negative control (no peptide
sensitization). In E781–95 (#21), amino acid position 81, 82 (N-terminus) and 92, 94, 95 (C-terminus) for HLA-A*02:02
and 24:02, and 81, 82 (N-terminus) and 92, 95 (C-terminus) for HLA-A*11:01 and 33:03 were important to elicit Th1
response of PBMCS. In E789–103 (#23), residue 100 and103 (C-terminus) were important to elicit the CD8
+ CTL
response in HLA-A*02:01, 11:01 and 33:03 and 100, 101, and 103 (C-terminus) were important to elicit the CD8+
CTL response in HLA-A*24:02.
Conclusions: E781–95 (#21) and E789–103 (#23) were identified as novel epitopes from HPV18 E7 which could
sensitized PBMCs of four different HLA class I (HLA-A*02:01, 24:02, 11:01 and 33:03). These epitopes could be useful
for immune monitoring and immunotherapy for HPV 18+ cervical cancer.
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A number of previous studies have reported that various
types of cancer are caused by Infectious pathogens such
as human papilloma virus (HPV), Helicobacter pylori,
and hepatitis viruses [1,2]. HPV has been proven as a
major causative pathogen of cervical cancer, anal cancer
and nasopharyngeal cancer. Cervical cancer is the third
most commonly diagnosed cancer and second leading
cause of cancer-related death worldwide in women [3,4]* Correspondence: jlim@yuhs.ac
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unless otherwise stated.and the incidence of nasopharyngeal cancer have been
markedly increased during last decade in both men and
women [5-8]. Therefore, the control of HPV infection is
critical for the prevention or treatment of not only in
precancerous states, but also in HPV-induced cancers.
Among over 100 subtypes of HPV, HPV 16 and 18 are
most important subtypes and about 70% of cervical can-
cers are associated with these two types of HPV [9].
Although currently available two prophylactic HPV vac-
cines have been shown to effectively prevent HPV-
associated anogenital disease in young women and men
[8,9], only 32% of teenagers who qualify for immunization
have received all three recommended doses of the vaccine. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 15-amino acid overlapping peptides spanning
the HPV type 18 E7 protein
Number Amino acid position Amino acid sequence
1 1-15 MHGPKATLQDIVLHL
2 5-19 KATLQDIVLHLEPQN
3 9-23 QDIVLHLEPQNEIPV
4 13-27 LHLEPQNEIPVDLLC
5 17-31 PQNEIPVDLLCHEQL
6 21-35 IPVDLLCHEQLSDSE
7 25-39 LLCHEQLSDSEEEND
8 29-43 EQLSDSEEENDEIDG
9 33-47 DSEEENDEIDGVNHQ
10 37-51 ENDEIDGVNHQHLPA
11 41-55 IDGVNHQHLPARRAE
12 45-59 NHQHLPARRAEPQRH
13 49-63 LPARRAEPQRHTMLC
14 53-67 RAEPQRHTMLCMCCK
15 57-71 QRHTMLCMCCKCEAR
16 61-75 MLCMCCKCEARIKLV
17 65-79 CCKCEARIKLVVESS
18 69-83 EARIKLVVESSADDL
19 73-87 KLVVESSADDLRAFQ
20 77-91 ESSADDLRAFQQLFL
21 81-95 DDLRAFQQLFLNTLS
22 85-99 AFQQLFLNTLSFVCP
23 89-103 LFLNTLSFVCPWCAS
24 93-107 TLSFVCPWCASQQ
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peutic effect on pre-existing cervical infection or cer-
vical lesions [11,12]. Moreover, conventional primary
treatments for early stage cervical cancer showed a re-
currence rate of about 15% [13,14]. In the case of late
stage or recurrent disease, treatment results are rela-
tively poor. Thus, more effective ways which can con-
trol or treat HPV infection and HPV-related cancer
should be needed.
Spontaneous regression of HPV-infected precancerous
lesions has been reported in patients who had strong
HPV-specific Th1-biased T-cell responses [15-18]. In
particularly, a strong CD8+ cytotoxic T lymphocyte (CTL)
response could play an important role not only for control
of HPV infection, but also for treatment of HPV-induced
cervical cancer. The peptides from the HPV protein could
successfully sensitize and expand HPV-specific CTLs and
these peptides can be used for immune monitoring as well
as for vaccine or immune therapy against HPV-induced
disease [19,20]. However, one of the major drawback limit-
ing the use of peptide-based immune monitoring or im-
munotherapy is that identification of at least one immune
dominant epitopes from HPV molecules for each HLA
class I alleles are needed for wide clinical application be-
cause CD8+ CTLs from patients or donors who have
different HLA class I genetic background recognized dif-
ferent epitopes of HPV molecules. For overcome this
drawback of peptide-based immune monitoring or im-
munotherapy, the identification of single peptides that can
bind to multiple HLA types have been investigated and
theses could lead to effective coverage of the human
population by a peptide-based immune monitoring or im-
munotherapy. However, very few studies have addressed
PBMC recognition of single peptides in a genetically het-
erogeneous group previously exposed to an infectious
agent or cancer [21-24].
In this study, we report that novel single peptides that
can bind to 4 different HLA class I which are A*02:01,
A*24:02, A*11:01 and A*33:03, most frequent allele in
human race. Theses single peptides were successfully
elicit HPV 18-speciifc Th 1 responses of PBMCs.
Methods
Donors and peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were col-
lected from four HLA class I (HLA-A*02:01, A*24:02,
A*11:01, A*33:03) healthy donors. Human leukocyte
antigen (HLA) class I genotypes were determined by the
HLA laboratory at the Seoul Medical Science Institute
(Seoul, South Korea) via sequence-specific polymerase
chain reaction using genomic DNA. PBMCs were isolated
via density gradient centrifugation using Ficoll-Hypaque
1.077 (Pharmacia Biotech, Wilkstrom, Sweden). The
mononuclear cells were cryopreserved at −160°C inhuman AB + serum containing 10% dimethylsulfoxide
(DMSO; Sigma, St Louis, MO, USA). This research was
approved by the institutional review board of Yonsei Uni-
versity Health System, and all participants provided writ-
ten informed consent.Synthesis of HPV16 E7 peptides
A total of twenty-four, 15-amino acid peptides spanning
the HPV18 E7 protein that overlapped by 11 residues,
were synthesized commercially (purity of >95%; A &
Pep, Yeongi-gun, South Korea; Table 1). After selection
of the immune dominant candidate 15-amino acid pep-
tides which were restricted to each HLA class I from the
peptide library by screening and confirmation tests,
truncated peptides spanning the candidate 15-amino
acid peptides were synthesized (Table 2). The peptides
were diluted to working solution concentrations (1 μg/μL)
in diethylpyrocarbonate-treated water (Invitrogen, Carlsbad,
CA, USA) containing 1% DMSO and stored at −80°C be-
fore testing.
Table 2 HPV type 18 E781–95 and E89–103 truncated peptides
Number Amio acid position Amino acid sequence Number Amio acid position Amino acid sequence
21-1 82-95 DLRAFQQLFLNTLS 23-1 90-103 FLNTLSFVCPWCAS
21-2 83-95 LRAFQQLFLNTLS 23-2 91-103 LNTLSFVCPWCAS
21-3 84-95 RAFQQLFLNTLS 23-3 92-103 NTLSFVCPWCAS
21-4 85-95 AFQQLFLNTLS 23-4 93-103 TLSFVCPWCAS
21-5 86-95 FQQLFLNTLS 23-5 94-103 LSFVCPWCAS
21-6 87-95 QQLFLNTLS 23-6 95-103 SFVCPWCAS
21-7 88-98 QLFLNTLS 23-7 96-103 FVCPWCAS
21-8 81-94 DDLRAFQQLFLNTL 23-8 89-102 LFLNTLSFVCPWCA
21-9 81-93 DDLRAFQQLFLNT 23-9 89-101 LFLNTLSFVCPWC
21-10 81-92 DDLRAFQQLFLN 23-10 89-100 LFLNTLSFVCPW
21-11 81-90 DDLRAFQQLFL 23-11 89-99 LFLNTLSFVCP
21-12 81-89 DDLRAFQQLF 23-12 89-98 LFLNTLSFVC
21-13 81-88 DDLRAFQQL 23-13 89-97 LFLNTLSFV
21-14 81-87 DDLRAFQQ 23-14 89-96 LFLNTLSFV
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peptide-specific CTLs
Autologous dendritic cells (DCs) were generated as
previously described, with minor modifications [25,26].
PBMCs were incubated for 2 h at 37°C using complete
RPMI medium containing 10% fetal bovine serum
(FBS). Adherent monocytes were resuspended at a con-
centration of 5 × 106 cells/mL in complete RPMI
medium with granulocyte-macrophage colony-stimulating
factor (1500 IU/mL; PeproTech, Rocky Hill, NJ, USA) and
interleukin (IL)-4 (1200 IU/mL; PeproTech). On days 2, 4,
and 6 of culture, fresh cytokines were added. On day 5 of
culture, 10 ng/mL of tumor necrosis factor-α (R&D Sys-
tems, Minneapolis, MN, USA) was added for DC matur-
ation. After maturation, autologous DCs were pulsed with
peptides for at least 6 h. PBMCs were plated at a concen-
tration of 2 × 106 cells per well in a 24-well culture plate
(Nunc, Rochester, NY, USA) with 2 mL of complete RPMI
medium. PBMCs were sensitized with synthetic HPV18
E7 peptides (10 μg/mL/well), and 1000 IU/mL/well of re-
combinant human IL-2 (rhIL-2; PeproTech) was added.
Additionally, rhIL-2 (1000 IU/mL/well) was added to the
culture every other day. For 1-week expansion, peptide-
pulsed autologous DCs (4–10 × 106/well) were added to
the PBMCs on day 7, incubated for 6 h, and analyzed with
flow cytometry. DC-treated PBMCs were cultured for an-
other 7 days, and cytotoxicity assays were performed.
Intracellular flow cytometric analysis
Phycoerythrin (PE)-conjugated anti–interferon-gamma
(anti-IFN-γ), APC-Cy7-conjugated anti-CD44, FITC-
conjugated anti-CD3, PerCp-Cy5.5-conjugated anti-CD4,
and APC-conjugated anti-CD8 were purchased from BD
Biosciences (San Jose, CA, USA). For each sample, 1 × 105events were gated on a LSR II flow cytometer (BD Biosci-
ences, Franklin Lakes, NJ, USA). For data analysis (Flowjo
software; Tree Star, Ashland, OR, USA), positive cells were
expressed as a percentage of the respective reference
population. The assessment of responses was previously
described in more detail [24]. Briefly, peptide-sensitized
PBMCs (1 × 106 cells/mL) stimulated with phytohem-
agglutinin (PHA, Sigma) and PBMCs pulsed with autolo-
gous DCs that were not loaded with any peptide were
used as positive and negative controls, respectively. One
hour after stimulation, 10 μg of Brefeldin A (Sigma) was
added to each well. After 5 additional hours of incubation,
PBMCs were washed once with phosphate-buffered saline
(PBS) and then incubated in PBS containing 1 mM
ethylene-diamine-tetraacetic acid for 10 min. After 2 add-
itional washes with PBS containing 5% FBS, the cells were
incubated with fluorescently-labeled monoclonal anti-
CD3, anti-CD8, anti-CD4, anti-CD44, and anti–INF-γ
antibodies for 15 min on ice in the dark prior to analysis.
IFN-γ enzyme-linked immunosorbent spot assay (ELISpot)
IFN-γ production was determined in PBMCs stimulated
with HPV18 E7 peptides. Cryopreserved PBMCs were
thawed into complete RPMI (RPMI supplemented with
L-Glutamine, penicillin, streptomycin, and 10% heat
inactivated fetal calf serum; Invitrogen). Then, 5 × 105
cells/well were plated in triplicate for each treatment in
the ELISpot plates (Millipore, Billerica, MA, USA).
Plates were previously coated with anti-IFN-γ antibody
(Clone AN-18, Ebioscience, San Diego, CA, USA) at 4°C,
overnight. PBMCs were incubated with HPV18 E7 pep-
tides for 48 h at 37°C and 5% CO2. Phytohemagglutinin
(PHA) was added at 2.5 μg/mL as a positive control and
PBMCs sensitized with no peptide were used as a negative
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Figure 1 (See legend on next page.)
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Figure 1 Screening of immunogenic epitopes of HPV18 E7 which could sensitize PBMCs of four major HLA class I using IFN-γ ELISpot
assay. ELISpot assays were performed to measure IFN-γ production from donor’s PBMCs of four major HLA class I that were sensitized with 24
candidate peptides. HPV18 E781–95 (#21) and E789–103 (#23) induced greater number of IFN-γ
+ spots from PBMCs of HLA-A*02:01 (A), HLA-A*24:02
(B), HLA-A*11:01 (C), HLA-A*33:03 (D) than other peptides. Data are representative of at least three independent experiments using PBMCs from
HLA-A*02:01, HLA-A*24:02, HLA-A*11:01, HLA-A*33:03 subjects. PBMCs sensitized with PHA were used as a positive control (PHA), and PBMCs with
sensitized with no peptide (No peptide) were used as the negative control (N.C). Data are presented as mean ± standard error. Statistically significant
differences between the tested group and negative control group were determined using a student t-test (two-tailed). **P < .001; *P < .05.
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1 μg/mL in PBS) was added to each well (clone R4-6A2,
Ebioscience, San Diego, CA, USA) and incubated at RT
for 1.5 hours. After washing the plate 5 times with PBS,
100 μl of streptavidin-alkaline phosphatase (Invitrogen)
diluted 1:1000 in PBS was added. The plate was incubated
at RT for 1 h in the dark and developed with color solu-
tion by mixing 10 mL of Tris-MgCl2 buffer with 100 μL of
NBT solution (Bio-Rad, Berkeley, CA, USA) and 100 μL of
BCIP solution (Bio-Rad). The plate was dried before read-
ing. The spots were quantified with an ELISpot plate
reader and software version 3.5 (AID ELISpot Reader Sys-
tem, Strassberg, Germany). Data were obtained by calcu-
lating the means of triplicate wells. ELISpot data were
expressed as the total IFN-γ spot-forming units (SFU)/106
PBMCs.
Cell culture
The human HPV 18+, cervical cancer cell lines (HTB-34
for HLA-A*02:01, SNU-1160-A*2402) were purchased
from by the Korean Cell Line Bank (Seoul, Korea), and it
has been tested and authenticated. Cancer cell line was
expanded and frozen in aliquots within 4 weeks of pur-
chase. Cancer cells were thawed and cultured at 37°C
and 5% CO2 in Dulbecco’s modified Eagle medium
(Gibco, Grand Island, NY, USA) containing 10% FBS
and 1% antibiotics for no more than 8 passages.
Immortalized Epstein-Barr virus-B lymphoblastoid cell
lines (EBV-BLC) which were restricted each HLA class I
(kindly gifted from Dr. David Stroncek, in NIH) were
cultured at 37°C and 5% CO2 in RPMI-1640 with 10%
FBS. Cells were routinely tested for the absence of
mycoplasma.
In vitro cytotoxicity assay
Cytotoxicity assays were performed using the 51Cr re-
lease assay. Briefly, cervical cancer cells labeled for
45 min with 51Cr (100 mCi/106 cells; Perkin Elmer,
Waltham, MA, USA), washed in PBS, and dispensed in
triplicate into 96-well U-bottom plates (Nunc, Rochester,
NY, USA) at 4 × 103 cells/well. Peptide-sensitized
PBMCs were added at an effector: target ratio of either
10:1, 30:1, 50:1, or 100:1. The cells were pelleted and in-
cubated for 6 h, and the supernatant was analyzed using
a WIZARD2 Automatic Gamma Counter (Perkin Elmer).Spontaneous and total release for each target were used to
calculate the percentage of specific release according to
the following formula: % specific release = (experimental
counts per minute – spontaneous counts per minute)/
(total counts per minute – spontaneous counts per
minute) × 100.Statistical analysis
Data presented as mean ± standard error are the repre-
sentative of at least 3 different experiments. To compare
between control group and each tested group, a student
t-test (two-tailed) was used. P-values less than 0.05 was
considered statistically significant.Results
Screening of 15-amino acid peptides from HPV 18 E7 for
elicit of Th1 response
IFN-γ+ spot forming unit (SFU) were counted using ELI-
Spot assay after in vitro sensitization of PBMCs with
each candidate peptide to determine which 15-amino
acid peptides, from the 24 candidate peptides, were
able to elicit CTL-specific immune responses. In HLA-
A*02:01, A*11:01 and A*33:03, HPV 18 E789-103
LFLNTLSFVCPWCAS (#23) and HPV 18 E781-95
DDLRAFQQLFLNTLS (#21) consistently induced the
highest and 2nd highest production of IFN-γ+ spots
from PBMCs among 24 candidate peptides, respectively
(Figure 1A, C, D). In HLA-A*2402, E781–95 (#21) induced
the highest production of IFN-γ + spots and E789–103
(#23) was 2nd highest production of IFN-γ + spots from
PBMCs among 24 candidate peptides (Figure 1B). E789–103
(#23) and E781–95 (#21) induced at least 3 fold higher
numbers of IFN-γ + spot forming units (SFU) from
PBMCs than those of negative control (PBMCs sensitized
with no peptide) in all four HLA class I (P < 0.05, P < 0.05,
respectively). These results indicated that HPV18 E781–95
(#21) and E789–103 (#23) could induce strong Th1 re-
sponse from donor PBMCs of HLA-A*02:01, A*24:02,
A*11:01, A*33:03 simultaneously. Because Th1 response
was mainly induce by CD8+ and CD4+ T cells as well as
NK cells and the CD8+ CTLs play a major role in anti-
viral and anti-tumor responses, we further investigated to
determine whether these two candidate peptides induce
CD8+ CTL response using flow cytometry analysis.
AB
C
D
Figure 2 (See legend on next page.)
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Figure 2 Fold increase of the percentage of CD8 + IFN-γ +within donor’s PBMCs of four major HLA class I after sensitization of
candidate peptides. The percentage of CD8+IFN-γ+ from donor’s PBMCs of four major HLA class I were measured to determine whether the
CD8+ CTL response were induced by sensitization of donor PBMCs with candidate peptides and the fold increase of the percentage of CD8+IFN-γ+
within the total CD8+ T cell population in donor PBMCs after re-sensitization of each candidate peptide were compared to that of negative control
(PBMCs sensitized with no peptide). HPV18 E781-95DDLRAFQQLFLNTLS (#21) and E789-103LFLNTLSFVCPWCAS (#23) consistently induced higher the
percentage of CD8+IFN-γ+ T cells than that of other candidate peptides in HLA-A*02:01 (A), HLA-A*24:02 (B), HLA-A*11:01 (C), HLA-A*33:03 (D). PBMCs
sensitized with PHA were used as a positive control (PHA), and PBMCs sensitized with no peptide (No peptide) were used as the negative control
(N.C). Data are presented as mean ± standard error.
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15-amino acid peptides
We measured the intracellular IFN-γ production from
four HLA class I (HLA-A*02:01, A*24:02, A*11:01,
A*33:03) donor’s PBMCs to determine if the CD8+ CTL
response could be induced by sensitization of donor
PBMCs with candidate peptides. After a week of in vitro0.0
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Figure 3 EBV-BCLs cytotoxicity of PBMCs sensitized with HPV 18 E781
E789-103 (#23)-sensitized CTLs lysed more EBV-BLCs with E781-95 (#21) and E7
peptide) in all HLA-A*02:01 (A), A*24:02 (B), A*11:01(C), A*33:03 (D). PBMCs sen
PBMCs sensitized with no peptide and E789-105-loaded EBV-BCLs were used as
experiments using PBMCs from HLA-A*02:01, HLA-A*24:02, HLA-A*11:01, HLA-Asensitization, PBMCs were restimulated with dendritic
cells derived from autologous monocytes that were
loaded with each candidate peptide. After a 6-hour
resensitization, intracellular IFN-γ production from do-
nor’s CD8+ T cells (CD3+CD8+IFN-γ+) was measured by
flow cytometry. The fold increases of the percentage of
CD8+ T cells that produced intracellular IFN-γ (CD3+0.0
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sitized with E781-95 or E789-105 with EBV-BCLs loaded with no peptide or
negative controls. Data are representative of at least three independent
*33:03 subjects. Data are presented as mean (point) ± standard error (bar).
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among the total CD3+CD8+ T cell population were cal-
culated and compared to that of the negative control
(CD3+CD8+IFN-γ + among PBMCs sensitized with no
peptide) (Figure 2). HPV18 E781–95 (#21) and E789–103
(#23) consistently induced higher percentage of CD3+
CD8+IFN-γ+ than that of other candidate peptides in
HLA-A*02:01, A*24:02, A*11:01, A*33:03. E781–95 (#21)
and E789–103 (#23) showed at least 2-fold and 2.5-fold
higher induction of CD8+IFN-γ+ T cells compared to the
negative control in HLA-A*02:01, A*24:02, A*11:01,
A*33:03, respectively.
These results suggested that E781–95 (#21) and E789–103
(#23) could successfully induce CD8+ CTL response from
PBMC and these two peptides were selected for further
study.
Analysis of the peptide-specific cytotoxicity of E781–95
(#21) and E789–103 (#23) peptides
To confirm that HPV18 E781–95 (#21) and E789–103 (#23)
are immune-dominant peptides for each HLA class I
subjects, PBMCs from four HLA class I donors (HLA-
A*02:01, A*24:02, A*11:01, A*33:03) were sensitized
in vitro for two weeks with the candidate peptides and
were tested for cytotoxic effects using the HLA-matched
EBV-BLCs as the target cells because EBV-BLCs could
present each peptide successfully in the HLA-peptide
complex on their cell surface. HPV18 E781–95 (#21)- and
E789–103 (#23)-sensitized CTLs lysed more EBV-BLCs
loaded with E781–95 (#21) and E789–103 (#23, respectively,
than negative control (EBV-BLCs loaded with no peptide)A
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Figure 4 Cervical cancer cell cytotoxicity of PBMCs sensitized with HP
with HLA-matched cervix cancer cell lines were tested using the 51Cr-relea
PBMCs could successfully recognized same peptides that naturally presented
PBMCs of HLA-A*02:01 and HLA-A*24:02 lysed greater quantities of HTB-34 ce
(B) than that of negative control (PBMCs sensitized with no peptide), respecti
using PBMCs from HLA-A*02:01, HLA-A*24:02, HLA-A*11:01, HLA-A*33:03 subjin all HLA-A*02:01, A*24:02, A*11:01, A*33:03 (Figure 3A-D).
PBMCs sensitized for 2 weeks with E789–103 (#23) were
slightly higher cytotoxicity to HLA-matched EBV-BLCs
loaded with E789–103 (#23) than that of E781–95 (#21) in all
four HLA class I. These results confirmed that both HPV-
18 E781–95 (#21) and E789–103 (#23) were successfully rec-
ognized by CD8+ CTLs from 4 different HLA-A and
induced CD8+ cytotoxicity response in all four HLA class
I (HLA-A*02:01, A*24:02, A*11:01, A*33:03).
Cervical cancer cell cytotoxicity of PBMCs sensitized with
E781–95 (#21) and E789–103 (#23) peptides
To confirm the cervical cancer cell cytotoxicity of PBMCs
sensitized E781–95 (#21) and E789–103 (#23) peptides,
PBMCs from four HLA-A*02:01, A*24:02 donors were
sensitized with E781–95 (#21) and E789–103 (#23) peptides
in vitro for two weeks and were tested for cytotoxic effects
on the HLA-matched cervical cancer cell line (HTB-34 re-
stricted to HLA-A*02:01 and SNU-1160 restricted to
HLA-A*24:02). The cytotoxicity assay was carried out by
measuring 51Cr release from each HLA-restricted cancer
cells. HPV18 E781–95 (#21)- and E789–103 (#23)-sensitized
PBMCs lysed more cervical cancer cells than the unsensi-
tized cells. PBMCs from HLA-A*02:01 donors that were
in vitro-sensitized for 2 weeks with HPV18 E789–103 (#23)
and E781–95 (#21) were highly cytotoxic to HLA-A*02:01-
restricted HTB-34 cell lines (Figure 4A). PBMCs from
HLA-A*24:02 donors that were in vitro-sensitized for
2 weeks with HPV18 E789–103 (#23) and E781–95 (#21)
were also highly cytotoxic to SNU-1160 cells (Figure 3B).
These results confirmed that both HPV-18 E781–95 (#21)0.0
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Figure 5 Determination the fine specific residues within the 15-aa epitopes recognized by PBMCs using IFN-γ ELISpot assay. IFN-γ ELISpot
assays were performed to determination the fine specific residues within HPV18 E781–95(#21) and E789–103 (#23) which were recognized by PBMCs. In
HLA-A*02:01 (A), residue 82 of the N-terminus and 92, 94 of C-terminus within HPV18 E781–95 (#21) were important to elicit Th1 response of PBMCS.
Residue 100, 103 of C-terminus within E789–103 (#23) were important to elicit the cytotoxic response of PBMCs. In HLA-24:02 (B), residue 82 of the
N-terminus and 92, 94 of C-terminus within HPV18 E781-95 (#21) were important to elicit Th1 response of PBMCS. Residue 100, 101, 103 of C-terminus
within E789-103 (#23) were important to elicit the cytotoxic response of PBMCs. In HLA-A*11:01 (C) and 33:03 (D), residue 82 of the N-terminus and 94
of C-terminus within HPV18 E781–95 (#21) were important to elicit Th1 response of PBMCS. Residue 100, 103 of C-terminus within E789–103 (#23) were
important to elicit the cytotoxic response of PBMCs. Data are representative of at least three independent experiments using PBMCs from HLA-A*02:01,
HLA-A*24:02, HLA-A*11:01, HLA-A*33:03 subjects. Data are presented as mean ± standard error. Statistically significant differences between the tested
group and negative control group were determined using a student t-test (two-tailed). **P < .001; *P < .05.
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both HTB-34 and SNU-1160 cervical cancer cell lines and
were to be useful as the HLA-A*02:01 and HLA-A*24:02
immunogenic epitopes within the HPV18 E7 protein.
Determination of the specific residues within E781–95 (#21)
and E789–103 (#23) epitopes recognized by CD8
+ CTLs
To determine the specific residues within E781–95 (#21)
and E789–103 (#23) epitopes recognized by CD8
+ CTLs, a
panel of N- and C-terminal truncations of HPV18 E781–95
(#21) and E789–103 (#23) was synthesized (Table 2) and
tested using ELISpot assay (Figure 5). In all four HLA
types, the stepwise removal of amino acids from the N-
terminal end of the HPV-18 E781–95 (#21) revealed that
the Th1 response was diminished when residue 82 was de-
leted. This result suggested that residue 81 and 82 of the
N-terminus were important to elicit Th1 response of
PBMCs in four different HLA class I (Figure 5A-D). In
case of HLA-A*02:01 and HLA-24:02, truncations from
the C-terminal side of HPV-18 E781–95 (#21) revealed that
residue 92, 94, and 95 were important for the CD8+ CTL
response. These results indicate that residues 92, 94 and
95 would mark the C-terminal edge of the CD8+ CTL-
stimulating epitope (Figure 5A and B). However, in case of
HLA-A*11:01 and HLA-33:03, residue 94 and 95 were im-
portant for the PBMCs response, and these residues
would mark the C-terminal edge of the CD8+ CTL-
stimulating epitope (5C, 5D).
In HLA-A*02:01, A*11:01 and A*33:03, truncations
from the C-terminal end of HPV18 E789–103 (#23) re-
vealed that residue 100 and 103 were important to elicit
the CD8+ CTL response. This suggested that residues
100 and 103 comprise the C-terminal end of the CD8+
CTL-stimulating epitope (5A, 5C, 5D). However, in case
of HLA-A*24:02, residue 100, 101 and 103 were import-
ant to elicit the CD8+ CTL response and residues 100,
101 and 103 comprise the C-terminal end of the CD8+
CTL-stimulating epitope (5B).
Truncated peptides of HPV-18 E781–95 (#21) and E784–99
(#23) induced the peptide-specific cytotoxicity
To provide further evidence that truncated peptides of
HPV18 E781–95 (#21) and E784–99 (#23) induced epitope-specific and HLA class I-restricted cell cytotoxicity,
PBMCs were sensitized with the truncated peptides and
tested for cytotoxicity, using the 51Cr release assay with
HLA-matched EBV-BLCs loaded with same peptides. In
case of HLA-A*02:01 and A*24:02, HPV18 E782-95
DLRAFQQLFLNTLS (#21-1), E781-94DDLRAFQQLFLNTL
(#21-8), and E781–92 DDLRAFQQLFLN (#21-10) from
HPV18 E781–95 (#21)-sensitized CTLs lysed greater quan-
tities of EBV-BLCs than that of negative control cells
(EBV-BLCs loaded with no peptide or PBMCs sensitized
with no peptide) (Figure 6A and C). In HLA-A*11:01 and
A*33:03, HPV18 E782-95DLRAFQQLFLNTLS (21–1) and
E781–92 DDLRAFQQLFLN (21–10) from HPV18 E781–95
(#21)-sensitized CTLs lysed greater quantities of EBV-
BLCs than that of negative control cells (EBV-BLCs pulsed
with no peptide (Figure 6E and G). In case of HLA-
A*02:01, A*11:01 and A*33:03, CTLs sensitized with E784–97
LFLNTLSFVCPW (#23-10) from HPV18 E789–103 (#23)
lysed greater quantities of EBV-BLCs loaded with same
peptide than the negative controls (EBV-BLCs loaded
with no peptide or PBMCs sensitized with no peptide))
(Figure 6B, F, H). In HLA-A*24:02, CTLs sensitized
with E784–98 LFLNTLSFVCPWC (23–9) and E784–97
LFLNTLSFVCPW (23–10) from HPV18 E789–103 (#23)
lysed greater quantities of EBV-BLCs pulsed with same
peptide than the negative controls (EBV-BLCs loaded with
no peptide) (Figure 6D). These results were comparable to
the results of ELISpot assays in Figure 5.
Discussion
A strong Th1-biased T-cell response is important for
control or elimination of not only infection of HPV 16
and 18 in precancerous disease, but also HPV-induced
cervical cancer. E6 and E7 protein of HPV have been
suggested as good targets for immune monitoring or im-
munotherapy against HPV-associated disease because E6
and E7 are constitutively expressed in both HPV-
infected cells and cervical cancer cells and are not
express in normal cervical epithelia. Therefore, the iden-
tification of CTL specific epitopes from E6 and E7 pro-
teins of HPV 16 and 18 is essential for the development
of peptide-based immune monitoring of HPV-specific
CTL response and immunotherapy in patients. However,
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Figure 6 Truncated peptides of HPV-18 E781–95 (#21) and E784–99 (#23) induced the peptide-specific cytotoxicity. PBMCs were sensitized
with truncated peptides and tested for cytotoxicity using the 51Cr release assay against HLA-matched, truncated peptide-loaded EBV-BLCs. In
HLA-A*02:01, truncated peptides #21-1, #21-8, #21-10 and #23-10-sensitized CTLs lysed more EBV-BLCs loaded with same peptide, respectively,
than negative control (A,B), In HLA-A*24:02, #21-1, #21-8, #21-10 and #23-9, #23-10-sensitized CTLs lysed more EBV-BLCs loaded with same
peptide, respectively, than negative control (C,D). In HLA-A*11:01, #21-1, #21-10 and #23-10-sensitized CTLs lysed more EBV-BLCs loaded with same
peptide, respectively, than negative control (E,F). In HLA-A*33:03, #21-1, #21-10 and #23-10-sensitized CTLs lysed more EBV-BLCs loaded with
same peptide, respectively, than negative control (G,H). PBMCs sensitized with truncated-peptide and EBV-BCLs loaded with no peptide were used as
the negative control. Data are representative of at least three independent experiments using PBMCs from HLA-A*02:01, HLA-A*24:02, HLA-A*11:01,
HLA-A*33:03 subjects. Data are presented as mean (point) ± standard error (bar).
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ive peptide-base immune monitoring or immunotherapy
is the fact that different epitopes are recognized by T
cells from individuals displaying distinct major HLA
molecules. Moreover, although HPV 18 is second most
common subtype after HPV 16 which is associated with
cervical cancer, only few CTL-specific epitopes of
HPV18 have been identified.
Until very recently, the studies searching for immune
dominant peptides were performed testing of substantial
numbers of overlapping peptides or peptide libraries.
The identification of major HLA-binding motifs allowed
the prediction of potential T cell epitopes (21,22), and
supertypes or single peptide which can sensitize multiple
HLA molecules simultaneously were found (23). How-
ever, very few studies have addressed CTL recognition of
single peptide in a genetically heterogeneous group pre-
viously exposed to HPV infection or cervical cancer.
In this study, we found that two overlapping 15-amino
acid peptides from HPV 18 E7 protein, E781-95
DDLRAFQQLFLNTLS (#21) and E789-103LFLNTLSFVC
PWCAS (#23), which could sensitize PBMCs of four major
HLA class I A molecules including HLA-A*02:01, A*24:02,
A*1101, and A*33:03, simultaneously. These four major
HLA class I alleles are the most frequent HLA class I allele
in human race. These 15-amino acid peptides were also
successfully recognized by CD8+ CTLs of four different
HLA class I alleles.
In the screening test, E781–95 (#21) and E789–103 (#23)
were selected because these peptides induced most
strong IFN-γ responses from PBMCs of four different
HLA class I than other peptides (Figure 1A-D). How-
ever, IFN-γ could be released from many kinds of im-
mune cells, including CD8+ and CD4+ T cells and NK
cells. Thus, to determine if IFN-γ was produced from
CD8+ T lymphocytes, CD3+CD8+IFN-γ+ T cells were
counted using flow cytometry, and HPV-18 E781–95
(#21) and E789–103 (#23) induced greater numbers of
CD3+CD8+IFN-γ+ T cells than other peptides and nega-
tive control (PBMCs sensitized with no peptide) in all
four different HLA types (Figure 2A-D). HPV18 E781–95
(#21)- and E789–103 (#23)-sensitized CTLs lysed more
EBV-BLCs loaded with E781–95 (#21) and E789–103 (#23),
respectively, than negative control (EBV-BLCs with nopeptide) in all four HLA types (Figure 3A-D). It sug-
gested that these epitopes successfully bound to HLA-
A*02:01, 24:02, 11:01 and 33:03 molecules on the surface
of EBV-BLCs and also were successfully recognized by
CD8+ CTLs within the PBMCs that were in vitro sensi-
tized with same peptides. HPV18 E781–95 (#21)- and
E789–103 (#23)-sensitized HLA-A*02:01 and 24:02
PBMCs also lysed more HLA-matched cervical cancer
cell lines (HTB-34 and SNU-1160, respectively) than
negative control (PBMCs sensitized with no peptide)
(Figure 5A, B). These results confirmed that both HPV-
18 E781–95 (#21) and E789–103 (#23) epitopes were natur-
ally processed in both HTB-34 cell lines and SNU-1160
cell lines and were to be useful HLA-A*02:01 and HLA-
A*24:02 immunogenic epitopes within the HPV18 E7
protein. We only used HTB-34 and SNU-1160 for cyto-
toxicity assay against cervical cancer cell in this study
because these two cervical cancer cell lines were only
available HPV 18+ E7 expressed cell lines in ATCC and
Korean Cell Line Bank.
Virally infected human cells or human cancer cells can
be recognized by CD8+ CTLs through immunogenic epi-
topes of 8 to 12 amino acids that are presented on the
cell surface with HLA class I molecules. Thus, we used
truncated peptides to determine the critical residues that
induce CD8+ CTL responses within the 15-amino acid
peptides and to determine the position of MHC anchor
residues. Residue 81,82 of the N-terminus of E781–95
(#21) were important to elicit Th1 response of PBMCS
in all four HLA class I (Figure 5A-D). Residue 92, 94, 95
would mark the C-terminal edge of the CD8+ CTL-
stimulating epitope in HLA-A*02:01 and 24:02
(Figure 5A, B). In HLA-A*11:01 and 33:03, residue 94,
95 would mark the C-terminal edge of the CD8+ CTL-
stimulating epitope within E781–95 (#21) (5C, 5D). In
HLA-A*02:01, A*11:01 and A*33:03, residue 100 and
103 comprise the C-terminal end of the CD8+ CTL-
stimulating epitope in peptide #23 (5A, 5C, 5D). How-
ever, in case of HLA-A*24:02, residue 100, 101 and 103
comprise the C-terminal end of the CD8+ CTL-
stimulating epitope within E789–103 (#23) (5B). These re-
sults were comparable to the results of cytotoxicity
assays using PBMCs sensitized with truncated peptides
within E781–95 (#21) and E789–103 (#23), and HLA-
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tides in Figure 6.
In conclusion, we identified E781-95DDLRAFQQLFLNTLS
(#21) and E789-103LFLNTLSFVCPWCAS (#23), which
could sensitize PBMCs of four HLA class I A molecules
including HLA-A*02:01, A*24:02, A*11:01, and A*33:03,
simultaneously, and demonstrated that PBMCs sensitized
with these peptides showed cytotoxicity against cervical
cancer cells. These epitopes could be useful for immune
monitoring or immunotherapy against for HPV18-related
diseases including cervical cancer, anal cancer, and oro-
pharyngeal cancer.
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